Literature DB >> 31389263

Recent advances in cryoballoon ablation for atrial fibrillation.

Thiago Guimarães Osório1, Hugo-Enrique Coutiño1, Pedro Brugada1, Gian-Battista Chierchia1, Carlo De Asmundis1.   

Abstract

Introduction: Pulmonary vein isolation (PVI), by catheter ablation, represents the current treatment for drug-resistant atrial fibrillation (AF). Nowadays cryoballoon (CB) is a recognized ablation method in patients with atrial fibrillation, mainly due to its ease of use, leading to reproducible and fast procedures. This novel single shot technology literally revolutionized the approach to AF ablation. Areas covered: The historical development of the cryoballoon, ablation techniques and new approaches beyond the ordinary PVI and complications are summarized here. Expert opinion: Although cryoballoon ablation has greatly standardized the approach to PVI a few critical points still need to be clarified scientifically in order to further uniform this procedure in cath labs worldwide. Duration and dosage of the cryoapplication is undoubtedly a topic of great interest.

Entities:  

Keywords:  Appendage isolation; atrial fibrillation; autonomic nervous system; catheter ablation; cryoablation; cryoballoon; ganglionated plexi; left atrial posterior wall isolation pulmonary vein isolation

Mesh:

Year:  2019        PMID: 31389263     DOI: 10.1080/17434440.2019.1653181

Source DB:  PubMed          Journal:  Expert Rev Med Devices        ISSN: 1743-4440            Impact factor:   3.166


  6 in total

1.  Temperature-guided ablation with the second-generation cryoballoon for paroxysmal atrial fibrillation: 3-year follow-up in a multicenter experience.

Authors:  Gaetano Paparella; Saverio Iacopino; Thiago Guimarães Osório; Juan Pablo Abugattas de Torres; Erwin Ströker; Juan Sieira; Hannes Vanacker; Bernard De Ruyter; Serge Boveda; Riccardo Maj; Gianluca Borio; Alessandro Rizzo; Alessio Galli; Pedro Brugada; Carlo de Asmundis; Gian-Battista Chierchia
Journal:  J Interv Card Electrophysiol       Date:  2020-05-31       Impact factor: 1.900

Review 2.  Innovations in atrial fibrillation ablation.

Authors:  Jitae A Kim; Khurrum Khan; Riyad Kherallah; Shamis Khan; Ishan Kamat; Owais Ulhaq; Qussay Marashly; Mihail G Chelu
Journal:  J Interv Card Electrophysiol       Date:  2022-04-11       Impact factor: 1.900

Review 3.  Catheter ablation for atrial fibrillation: current indications and evolving technologies.

Authors:  Ramanathan Parameswaran; Ahmed M Al-Kaisey; Jonathan M Kalman
Journal:  Nat Rev Cardiol       Date:  2020-10-13       Impact factor: 32.419

4.  Procedural Safety and Efficacy for Pulmonary Vein Isolation with the Novel Polarx™ Cryoablation System: A Propensity Score Matched Comparison with the Arctic Front™ Cryoballoon in the Setting of Paroxysmal Atrial Fibrillation.

Authors:  Joerelle Mojica; Felicia Lipartiti; Maysam Al Housari; Gezim Bala; Shuichiro Kazawa; Vincenzo Miraglia; Cinzia Monaco; Ingrid Overeinder; Antanas Strazdas; Robbert Ramak; Gaetano Paparella; Juan Sieira; Lucio Capulzini; Antonio Sorgente; Erwin Stroker; Pedro Brugada; Carlo De Asmundis; Gian-Battista Chierchia
Journal:  J Atr Fibrillation       Date:  2021-06-30

5.  Comparison between superior vena cava ablation in addition to pulmonary vein isolation and standard pulmonary vein isolation in patients with paroxysmal atrial fibrillation with the cryoballoon technique.

Authors:  Ingrid Overeinder; Thiago Guimarães Osório; Paul-Adrian Călburean; Antonio Bisignani; Gezim Bala; Juan Sieira; Erwin Ströker; Maysam Al Houssari; Joerelle Mojica; Serge Boveda; Gaetano Paparella; Pedro Brugada; Carlo de Asmundis; Gian-Battista Chierchia
Journal:  J Interv Card Electrophysiol       Date:  2021-01-15       Impact factor: 1.900

6.  Higher FT4 level within the normal range predicts the outcome of cryoballoon ablation in paroxysmal atrial fibrillation patients without structural heart disease.

Authors:  Yan Pei; Shaojie Xu; Haotian Yang; Zhongyuan Ren; Weilun Meng; Yixing Zheng; Rong Guo; Shuang Li; Dongdong Zhao; Kai Tang; Hailing Li; Yawei Xu
Journal:  Ann Noninvasive Electrocardiol       Date:  2021-07-11       Impact factor: 1.468

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.